2009年12月通期決算の純利益は75億4,000万ドルで、前年から23％増加。新型インフルエンザのワクチンの販売が好調で、収益を押し上げた。売上高は9％増の89億5,000万ドル。10－12月期は純利益が前年同期比26％増の15億6,000万ドル、売上高が4％増の328億ドルとなった。同社の実績は好調だが、インフルワクチン部門は変動が激しく、しかも一部の主要薬が特許切れを迎えることから、予防的なリストラ策として2014年までに8,000人を削減する。
\
| Cookie | 期間 | 説明 |
|---|---|---|
| cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |